B. Potential Solutions / CONCLUSIONS AND POTENTIAL SOLUTIONS / Myriad Genetics / /
Country
United States / /
Currency
USD / EUR / /
Event
FDA Phase / /
Facility
College of William / University of Utah Research Foundation / University of Pennsylvania / Yale University / /
IndustryTerm
biotechnology / manufacturing trade secrets / pharmaceutical industry / genetic research tools / distinctive chemical identity / cancer therapeutics / pharmaceutical / therapy for human disease / gene product / drug manufacturers / chemical bond / technology research tool / chemical entity / genetic technologies / chemical structure / genetic technology / /
MedicalCondition
ovarian cancer / potential cancer / common complex diseases / breast cancer / cancers / specific diseases / cancer / disease / diseases / single-gene disorders / human disease / /
MedicalTreatment
cancer therapeutics / /
Organization
B. District Court / College of William & Mary / Harvard Law School / Food and Drug Administration / Harvard / Department of Health and Human Services Advisory Committee on Genetics / the University of Pennsylvania / Department of Justice / Yale University / Congress / University of Utah / Petrie-Flom Center for Health Law Policy / Biotechnology / and Bioethics / United States Patent and Trademark Office / UN Court / US Federal Reserve / Utah Research Foundation / /
Person
Erika Jonietz / Maxwell R. Morgan / Obama / E. Richard Gold / Christie DiNapoli / Rochelle C. Dreyfuss / Robert Sweet / Benjamin Roin / Stephen J. McCormack / Gene Patents / Robert Mullan Cook-Deegan / Timothy Caulfield / Moore / Christopher M. Holman / Abigail Lauer / Melissa Wasserman / Frederic M. Scherer / KENT L. REV / Michael S. Mireles / Alan R. Williamson / Henry G. Grabowski / Birgit Verbeure / Donald Zuhn / Bryson / Mari Edlin / /
Harvard Journal of Law & Technology Volume 25, Number 1 Fall 2011 THE DISPARATE EFFECTS OF GENE PATENTS ON DIFFERENT CATEGORIES OF SCIENTIFIC RESEARCH Abigail Lauer*